Novel Irreversible Electroporation Ablation Combined with TLR Agonists and PD-1 Blockade Eradicates Metastatic Melanoma
Congratulations Deborah Anderson was awarded a grant from the College of Medicine, University of Saskatchewan
New drugs for metastatic luminal A breast cancer
Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy
The KH domain facilitates the substrate specificity and unwinding processivity of DDX43 helicase
Luminal A breast cancer resistance mechanisms and emerging treatments, in “Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance”.
Invited editors of Book Series for Elsevier Publications.
The CINs of Polo-Like Kinase 1 in Cancer
Bibliometric analysis of personalized humanized mouse and Drosophila models for effective combinational therapy in cancer patients
Identification of therapeutically relevant targets in telomerase overexpressing prostate cancers
Humanized yeast genetic interaction mapping predicts synthetic lethal interactions of FBXW7 in breast cancer
Congratulations Franco Vizeacoumar (CoI) with PI: Joyce Wilson and CoI: Darryl Falzarano were awarded COVID grant from CIHR
SARS-CoV2 therapeutic discovery through genetic screens and repurposing drugs that target essential virus-host interactions
Riley Plett (Anderson lab) passed her MSc defence on May 4, 2020. Her thesis is titled: "New therapies for CREB3L1-deficient triple negative breast cancer".